Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carnahan

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Biorxiv : the Preprint Server for Biology|November 18, 2024
A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoproteinAlexandra A Abu-Shmais, Luqiang Guo, Ahmed Magady Khalil, et al.
Cell Reports. Medicine|January 17, 2026
A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoproteinAlexandra A Abu-Shmais, Luqiang Guo, Ahmed Magdy Khalil, et al.
Biorxiv : the Preprint Server for Biology|August 3, 2021
Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA VaccineKevin J Kramer, Erin M Wilfong, Kelsey Voss, et al.
Cell|March 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
The Journal of Clinical Investigation|August 4, 2025
Corrigendum to Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individualsElaine C Chen, Pavlo Gilchuk, Seth J Zost, et al.
The Journal of Clinical Investigation|June 22, 2021
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Nature Communications|June 17, 2022
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccineKevin J Kramer, Erin M Wilfong, Kelsey Voss, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Biorxiv : the Preprint Server for Biology|November 18, 2024
A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoproteinAlexandra A Abu-Shmais, Luqiang Guo, Ahmed Magady Khalil, et al.
Cell Reports. Medicine|January 17, 2026
A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoproteinAlexandra A Abu-Shmais, Luqiang Guo, Ahmed Magdy Khalil, et al.
Biorxiv : the Preprint Server for Biology|August 3, 2021
Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA VaccineKevin J Kramer, Erin M Wilfong, Kelsey Voss, et al.
Cell|March 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
The Journal of Clinical Investigation|August 4, 2025
Corrigendum to Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individualsElaine C Chen, Pavlo Gilchuk, Seth J Zost, et al.
The Journal of Clinical Investigation|June 22, 2021
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Nature Communications|June 17, 2022
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccineKevin J Kramer, Erin M Wilfong, Kelsey Voss, et al.
Pageof 15